Related Experiment Video
Updated: Feb 28, 2026
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
Selective blast cell reduction in elderly patients with acute myeloid leukemia secondary to myelodysplastic syndrome
Kei Suzuki1, Kohshi Ohishi, Takao Sekine
1Internal Medicine, Matsusaka Chuo General Hospital, Mie, Japan.
Abstract:
The management of elderly patients with acute myeloid leukemia (AML) and a poor performance status is challenging. An 89-year-old man with AML secondary to myelodysplastic syndrome (MDS) and a poor performance status (4) underwent treatment with methylprednisolone (mPSL) (125 mg/body), which resulted in a remarkable reduction of blast cells in the peripheral blood. Neutrophil counts were maintained or increased. Although the suppression was of short duration, mPSL was useful for disease control because it selectively reduced blast counts while maintaining the patient's performance status. In vivo and in vitro findings suggested that mPSL had direct inhibitory actions on the survival of blast cells. On the basis of this experience, we gave the same mPSL dose to other elderly patients with MDS/AML (n=5) or AML-M4 (n=1) who had a poor performance status (3 or higher) and appeared unable to tolerate standard cytotoxic chemotherapies. Selective and significant blast cell reduction was observed in 4 of the 5 patients with MDS/AML, whereas no effects were seen in the AML patient. Although our experience is limited, these findings may provide a clue to understanding the mechanisms regulating the survival of blast cells of MDS/AML and indicate that mPSL may provide a benefit to a subset of these patients.
Insights
Methylprednisolone (mPSL) offers a potential treatment for elderly acute myeloid leukemia (AML) patients with poor performance status. This approach selectively reduced blast cells, aiding disease control without compromising patient condition.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Managing elderly patients with acute myeloid leukemia (AML) and poor performance status presents significant challenges.
- Standard cytotoxic chemotherapies are often not tolerated by this vulnerable patient population.
Observation:
- A case study involving an 89-year-old man with AML secondary to myelodysplastic syndrome (MDS) and poor performance status showed remarkable blast cell reduction after methylprednisolone (mPSL) treatment.
- mPSL selectively reduced blast counts while maintaining neutrophil levels and the patient's performance status.
- In vitro and in vivo studies suggested direct inhibitory effects of mPSL on blast cell survival.
Findings:
- In a small cohort of elderly patients with MDS/AML and poor performance status, mPSL administration led to selective and significant blast cell reduction in 4 out of 5 patients.
- One patient with AML-M4 did not respond to mPSL treatment.
- The observed effects suggest mPSL may be beneficial for a subset of MDS/AML patients.
Implications:
- These findings suggest a potential role for methylprednisolone in managing specific elderly patients with MDS/AML who cannot tolerate conventional chemotherapy.
- Further research is warranted to elucidate the mechanisms of blast cell survival regulation in MDS/AML and to confirm the therapeutic potential of mPSL in this patient group.
